BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Fargion S, Borzio M, Maraschi A, Cargnel A, Lombardo TPOTGE. Triple antiviral therapy in HCV positive patients who failed prior combination therapy. World J Gastroenterol 2006; 12(33): 5293-5300 [PMID: 16981257 DOI: 10.3748/wjg.v12.i33.5293]
URL: https://www.wjgnet.com/1007-9327/full/v12/i33/5293.htm
Number Citing Articles
1
P. LANGLET, F. D’HEYGERE, J. HENRION, M. ADLER, J. DELWAIDE, H. VAN VLIERBERGHE, J. P. MULKAY, L. LASSER, R. BRENARD, Y. HORSMANS, P. MICHIELSEN, A. LAUREYS, F. NEVENS. Clinical trial: a randomized trial of pegylated‐interferon‐α‐2a plus ribavirin with or without amantadine in treatment‐naïve or relapsing chronic hepatitis C patientsAlimentary Pharmacology & Therapeutics 2009; 30(4): 352 doi: 10.1111/j.1365-2036.2009.04052.x
2
Ronald L Koretz, Maria Pleguezuelo, Vasiliki Arvaniti, Pilar Barrera Baena, Ruben Ciria, Kurinchi Selvan Gurusamy, Brian R Davidson, Andrew K Burroughs. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CCochrane Database of Systematic Reviews 2013;  doi: 10.1002/14651858.CD003617.pub2
3
R. Chou, S. Carson, B. K. S. Chan. Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trialsJournal of Viral Hepatitis 2008; 15(8): 551 doi: 10.1111/j.1365-2893.2008.00984.x
4
A. G. Singal, A. K. Waljee, M. Shiffman, B. R. Bacon, P. S. Schoenfeld. Meta‐analysis: re‐treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapyAlimentary Pharmacology & Therapeutics 2010; 32(8): 969 doi: 10.1111/j.1365-2036.2010.04427.x